Clinical Trial Update: The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Revusiran (ALN-TTRSC) in patients with TTR-mediated amyloidosis after liver transplant has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attr Amyloidosis
• Familial Amyloid Neuropathies
• Familial Amyloidotic Polyneuropathy
• Transthyretin-mediated Amyloidosis

Drugs mentioned

• Revusiran (ALN-TTRSC)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP) | Phase 2 | Status: COMPLETED | Results posted: 2019-03-28